Identification of S6K2 as a centrosome-located kinase

• Published in: FEBS letters 2007-08, Vol.581 (21), p.4058-4064
• Main Authors: Rossi, Rossella, Pester, John M., McDowell, Mitch, Soza, Samuela, Montecucco, Alessandra, Lee-Fruman, Kay K.
• Format: Article
• Language: English
• Subjects: Cell Cycle - drug effects; Cell Cycle - physiology; Centrosome; Centrosome - enzymology; Enzyme Inhibitors - pharmacology; HeLa Cells; Humans; mammalian target of rapamycin; mTOR; Phosphatidylinositol 3-Kinases - metabolism; Protein Kinases - metabolism; Proto-Oncogene Proteins c-akt - metabolism; Ribosomal Protein S6 Kinases - antagonists & inhibitors; Ribosomal Protein S6 Kinases - metabolism; ribosomal S6 kinase 1; ribosomal S6 kinase 2; Ribosomal S6 kinase 2 (S6K2); S6K1; S6K2; Signal Transduction - drug effects; Signal Transduction - physiology; TOR Serine-Threonine Kinases; γ-Tubulin
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1016/j.febslet.2007.07.047

Ribosomal S6 kinase 2 (S6K2) acts downstream of the mammalian target of rapamycin (mTOR). Here, we show that some S6K2 localize at the centrosome throughout the cell cycle. S6K2 is found in the pericentriolar area of the centrosome. S6K2 centrosomal localization is unaffected by serum withdrawal or treatment with rapamycin, wortmannin, U0126, or phorbol-12-myristate-13-acetate (PMA). Unlike S6K2, S6 kinase 1 (S6K1) does not localize at the centrosome, suggesting the two kinases may also have nonoverlapping functions. Our data suggest that centrosomal S6K2 may have a role in the phosphoinositide-3-kinase (PI3K)/Akt/mTOR signaling pathway that has also been detected in the centrosome.